XML 43 R22.htm IDEA: XBRL DOCUMENT
v3.24.1

Shareholders’ Equity | 12 Months Ended
--- | ---
Dec. 31, 2023
Shareholders’ Equity [Abstract] |
SHAREHOLDERS’ EQUITY | NOTE 14 - SHAREHOLDERS’ EQUITY:
| a. | Share capital (*)
On May 2, 2022, the Company’s Board of Directors approved an amendment to the Company’s Bylaws, stating the number of authorized stocks to be increased, as described below:
| a. | Common stock- $0.0001 par value – authorized shares increase to 30,000,000 shares from 11,009,315 shares.
| b. | Non-voting common stock- $0.0001 par value-authorized shares remain 2,803,774 shares.
| c. | Redeemable Convertible Preferred stock- $0.0001 par value - authorized shares increase to 10,000,000 shares from 7,988,691 shares.
The Company’s issued and outstanding common stocks as of December 31, 2023, and 2022, are 3,007,745 and 1,737,986, respectively.
| b. | On May 16, 2022, the Company filed with the Secretary of State of the State of Delaware an amended and restated certificate of incorporation (the “A&R COI”), which became effective immediately. The A&R COI includes the Company’s total authorized shares of 42,803,774, of which 30,000,000 are authorized shares of common stock, 2,803,774 are shares of non-voting common stock and 10,000,000 are shares of redeemable convertible preferred stock.
| c. | Initial public offering (*):
On May 17, 2022, the Company finalized its IPO offering of an aggregate of 421,250 shares of common stock, including the partial exercise by the underwriter of its option to purchase 46,250 additional shares of common stock, at a price to the public of $40.00 per share. The net proceeds from the offering, including the over-allotment, to the Company were approximately $15.4 million, after deducting underwriting discounts, commissions and expenses amounting to approximately $1.0 million. As a result of the IPO, the Company issued common stock in the transactions described below:
| a. | Redeemable convertible preferred stock (see Note 12) - the Company issued 773,108 shares of common stock (on a one (1) for one (1) basis, pursuant to the conversion provisions of the Series A and Series B redeemable Preferred Stock agreements). Upon the conversion, the Company reclassified the Convertible Preferred stock at its carrying amount, from temporary equity, into shareholders’ equity.
| b. | Convertible loan agreement (“CLA”) (see Note 10) – the Company issued 163,816 shares of common stock. pursuant to the conversion features of the loan agreement.
Upon such issuance, the Company reclassified the Convertible loan’s carrying amount (which reflected its then current fair value), into shareholders’ equity.
| c. | Convertible notes (see Note 9) –The Company issued 90,009 shares of common stock pursuant to the conversion features of the note agreements issued during December 2021 and April 2022.
| d. | Warrants (See Note 13):
| 1. | The Company issued 61,756 shares of common stock as a result of the exercise provisions of the detachable warrants granted to Mizrahi-Tefahot Bank as part of the Company’s financing agreement with Bank Mizrahi.
| 2. | The Company issued 18,000 shares of common stock to Migdalor as a result of the exercise provisions of the detachable warrants granted to Migdalor as part of the loan agreement with Migdalor.
| 3. | In addition, concurrently with the IPO and in connection with the consummation of the IPO, the Company issued common stock warrants to the underwriters. The warrants are exercisable into 29,487 of the Company’s common shares for an exercise price of $50 per share and can be exercised at any time during a period of 5 years from the issuance date (i.e. until May 17, 2027). The warrants are classified as equity based on the guidance provided under ASC 718-10.
As of the issuance date of the underwriter warrants, the fair value of the warrants was estimated at $145. The valuation was based on a Black-Scholes option-pricing model, using an expected volatility of 54%, a risk-free rate of 3.01%, a contractual term of 5 years, an expected dividend yield of 0% and a stock price at the issuance date of $19.50 prior to the reverse split.
| e. | The Company redeemed 178,377 shares of non-voting common stock at their par value, removing the stock from shareholders’ equity.
| (*) | Adjusted to reflect reverse stock split, see note 2(ff).
| d. | Offering of common stocks and warrants
| a. | On May 8, 2023, the Company completed a fund-raising round in a total gross amount of $3.5 million pursuant to which the Company agreed to issue and sell to Armistice Capital Master Fund Ltd. (the “Holder”) in a private placement (the “Offering”):
| 1. | 190,000 shares of the Company’s common stock, $0.0001 par value;
| 2. | 754,670 pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 754,670 shares of Common Stock for an exercise price of $0.0001 which are exercisable (either physically or on a net-cash basis at the Holder’s discretion) immediately upon their issuance until their full exercise. Their exercise price is adjustable upon dilutive events (such as subsequent rights offerings, pro-rata distributions and stock dividends and splits). The Holder also has certain rights upon a fundamental transaction (as defined in the agreement) as specified in the agreement. The warrants were classified as equity pursuant to ASC 815-40.; and
| 3. | warrants to purchase up to 944,670 shares of Common Stock (“Common Warrants”) for an exercise price of $3.58 which are exercisable (physically or upon occurrence of certain events on net-cash basis at the Holder’s discretion) immediately upon their issuance until November 8, 2028. Their exercise price is adjustable upon dilutive events (such as subsequent rights offerings, pro-rata distributions and stock dividends and splits). The Holder also possesses a right to receive any additional consideration that holders of common stocks may be entitled to upon a fundamental transaction (as defined in the agreement).
The Company determined that the Common Warrants were not indexed to the Company’s own stock and therefore were excluded from equity classification and classified as warrant liabilities. The Common Warrants were measured at fair value at inception and in subsequent reporting periods with changes in fair value recognized as financial income or expense as change in fair value of warrant liabilities in the period of change in the consolidated statements of comprehensive loss. The Common Warrants were recorded at fair value on May 8, 2023, at $1,972, and the residual value was allocated to the common stock and pre-funded warrants which were classified as equity. The valuation was based on a Black-Scholes option-pricing model, using an expected volatility of 54%, a risk-free rate of 3.49%, a contractual term of 5.5 years and a stock price at the issuance date of $3.70. On September 30, 2023, the Company remeasured the common warrants at a fair value of $246. The valuation was based on a Black-Scholes option-pricing model, using an expected volatility of 54%, a risk-free rate of 4.60%, a contractual term of 5.1 years and a stock price of $1.10. The Company recorded other financial income (expenses) during 2023, in the amount of $1,726, in connection with the revaluation of these warrants to their fair value. On September 30, 2023, the Company and the Holder entered into a Common warrants amendment agreement (the “Amendment”) to amend the Common warrants to purchase up to 944,670 shares of the Company’s common stock, par value $0.0001 issued to the Holder. The Amendment made certain adjustments to the definition of a “Fundamental Transaction” in Common Warrant agreement. Additionally, the Amendment increased the number of Common Warrants to include an additional 55,000 Common warrants and changed the exercise price of the Common Warrants to $2.75. The Company reclassified the Common warrants as equity based on the guidance provided under ASC 815-40, due to the adjustments stated in the Amendment. As of the date of the amendment of the Common warrants, the fair value of the warrants was estimated at $314. The valuation was based on a Black-Scholes option-pricing model, using an expected volatility of 54%, a risk-free rate of 4.60%, a contractual term of 5.1 years and a stock price at the issuance date of $1.10. As a result of the Amendment, the Company recorded other financial expenses in 2023, in the amount of $68. During July and August 2023, the Holder elected to exercise 754,670 of the pre-funded warrant. The total exercise price in the amount of $0.0755 was paid in cash. Offering Costs related to May 2023 fund-raising: Upon the consummation of the Offering and pursuant to an agreement entered into with H.C. Wainwright & Co., LLC (the “Underwriter”), the Company has paid in cash to the Underwriter (and the escrow agent) a total amount of $291. The Company has also granted to the Underwriter upon the consummation of the Offering, warrants to purchase up to 66,127 of the Company’s common stocks which carry the same terms as the common stock warrants described above (Note 14d), except for the exercise price which reflected 125% of the share price in the Offering ($4.6313). The warrants are classified as mezzanine equity. As of the issuance date of the underwriter warrants, the fair value of the warrants was estimated at $104. The valuation was based on a Black-Scholes option-pricing model, using an expected volatility of 56%, a risk-free rate of 3.29%, a contractual term of 5.5 years and a stock price at the issuance date of 3.58. Out of the total offering costs, an amount of $223 related to the issuance of the Common Warrants was recognized as a financial expense in the Consolidated statement of comprehensive loss, and an amount of $172 related to the issuance of the Common stocks and the prefunded warrants was recognized in equity. The allocation of total offering costs between the warrants, common stocks and prefunded warrants was in the same proportion as the allocation of the total proceeds from the offering. b. On December 20, 2023, the Company completed a fund-raising round in a total gross amount of $1.5 million pursuant to which the Company agreed to issue and sell to the Holder in December’s private placement (the “Second Offering”):
| 1. | 301,000 shares of the Company’s common stock, $0.0001 par value;
| 2. | 970,187 pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 970,187 shares of Common Stock for an exercise price of $0.0001 which are exercisable (either physically or on a net-cash basis at the Holder’s discretion) immediately upon their issuance until their full exercise. Their exercise price is adjustable upon dilutive events (such as subsequent rights offerings, pro-rata distributions and stock dividends and splits). The Holder also has certain rights upon a fundamental transaction (as defined in the agreement) as specified in the agreement.
| 3. | warrants to purchase up to 1,271,187 shares of Common Stock (“Common Warrants”) for an exercise price of $1.18 which are exercisable (physically or upon occurrence of certain events on a net-cash basis at the Holder’s discretion) immediately upon their issuance until June 20, 2029. Their exercise price is adjustable upon dilutive events (such as subsequent rights offerings, pro-rata distributions and stock dividends and splits). The Holder also possesses a right to receive any additional consideration that holders of common stocks may be entitled to upon a fundamental transaction (as defined in the agreement).
In connection with the Second Offering, the Company also has agreed to amend the existing warrants to purchase up to an aggregate of 999,670 shares of the Company’s common stock that were previously issued in May 2023 (and amended in November 2023) at an exercise price of $2.75 per share, such that effective on the date of shareholder approval to amend the warrants, the amended warrants will have a reduced exercise price of $1.18 per share. In the event that the Shareholder Approval is not obtained, the warrant amendment shall be null and void and the provisions of the existing warrants shall remain unchanged. As of December 31, 2023, the shareholder approval was not obtained. The common stock, pre-funded warrants and the warrants were classified as equity pursuant to ASC 815-40. Offering Costs related to December 2023 fund-raising: Upon the consummation of the Second Offering and pursuant to an agreement entered into with H.C. Wainwright & Co., LLC (the “Underwriter”), the Company has paid in cash to the Underwriter (and the escrow agent) a total amount of $129. The Company has also granted to the Underwriter upon the consummation of the Second Offering, warrants to purchase up to 88,983 of the Company’s common stocks which carry the same terms as the common stock warrants described above (Note 14c.), except for the exercise price which reflect 125% of the share price in the Second Offering ($1.475). The warrants are classified as mezzanine equity based on the guidance provided under ASC 480-10-S99-3A and SAB Topic 14. E. As of the issuance date of the underwriter warrants, the fair value of the warrants was estimated at $55. The valuation was based on a Black-Scholes option-pricing model, using an expected volatility of 57%, a risk-free rate of 3.86%, a contractual term of 5.5 years and a stock price at the issuance date of 1.18. The total Second Offering costs in the amount of $230 was recognized in equity.
| e. | Stock repurchase program (*)
On November 17, 2022, the Company’s Board of Directors authorized a stock repurchase program pursuant to which the Company intends to repurchase up to $1.0 million of its outstanding common stock. The Board authorized the Company to purchase its common stock from time to time on a discretionary basis through open market or private transactions, through block trades, and pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, and other applicable legal requirements. Repurchases under the share repurchase program will be made at management’s discretion at prices management considers to be attractive and in the best interests of both the Company and its stockholders, subject to the availability of stock, general market conditions, the trading price of the stock, alternative uses for capital, and our financial performance. The repurchase program may be suspended, terminated, or modified at any time for any reason, including market conditions, the cost of repurchasing shares, the availability of alternative investment opportunities, liquidity, and other factors deemed appropriate. These factors may also affect the timing and amount of share repurchases. The repurchase program does not obligate us to purchase any particular number of shares. During 2023, the Company purchased 7,920 shares of its common stock, for a total price of $50.
| f. | Share-based compensation (*)
On June 30, 2015, the Company adopted the 2015 Equity Incentive Plan (“the 2015 Plan”). Under the 2015 Plan, the Board of Directors may grant up to 280 Incentive Share Options, Non-statutory shares options, share appreciation rights, restricted share and restricted share units (RSU’s) to employees, directors, and consultants. The exercise price of an option cannot be less than 100% of the fair market value of the underlying share of common stock on the date of grant for incentive share options (not less than 110% of the fair market value for shareholders owning more than 10% of all classes of share) as determined by the Board of Directors. The maximum option term is 10 years (five years for shareholders owning more than 10% of all classes of share). The 2015 Plan grants the Board of Directors the discretion to determine when the options granted become exercisable. In January 2016, the Company’s Board of Directors approved an additional quantity of 22 share options permitted to be granted under the 2015 Plan. Pursuant to the current Section 102 of the Israeli Tax Ordinance, which came into effect on January 1, 2003, options and RSUs may be granted through a trustee (i.e., Approved 102 Options) or not through a trustee (i.e., Unapproved 102 Options). The Subsidiary elected to grant its options and RSU’s through a trustee. As a result, the Subsidiary will not be allowed to claim as an expense for tax purposes in Israel the amounts credited to the employee as capital gains to the grantees, although it will generally be entitled to do so in respect of the salary income component (if any) of such awards when the related tax is paid by the employee.
| 1) | During the years ended December 31, 2023, and December 2022, the following awards were granted:
Award Type (2015 Plan) |  | Number of Awards in 2023 |  |  | Number of Awards in 2022 (*) |  |  | Vesting Conditions |  | Expiration Date
Options |  |  | 400 |  |  |  | 16,778 |  |  | Over 4 years from grant date-25% every year (from the second year- 2.08% each month) |  | 10th anniversary of Grant Date
RSU |  |  | 45,100 |  |  |  | 59,200 |  |  | Over 3 years from grant date |  |
| 2) | A summary of the Company’s share option activity under option plans is as follows:
|  | Number of Options |  |  | Weighted- Average Exercise Price |  |  | Weighted Average Remaining Contractual Life |
Outstanding – January 1, 2023 |  |  | 96,459 |  |  | $ | 4.89 |  |  |  | 5.34 |
Granted |  |  | 400 |  |  | $ | 1.48 |  |  |  | 9.71 |
Exercised |  |  | (2,489 | ) |  | $ | 0.90 |  |  |  |  |
Forfeited |  |  | (6,606 | ) |  | $ | 22.74 |  |  |  |  |
Outstanding – December 31, 2023 |  |  | 87,764 |  |  | $ | 3.63 |  |  |  | 4.11 |
Exercisable – December 31, 2023 |  |  | 80,064 |  |  | $ | 2.36 |  |  |  | 3.67 |
|  | Number of Options (*) |  |  | Weighted- Average Exercise Price (*) |  |  | Weighted Average Remaining Contractual Life |
Outstanding – January 1, 2022 |  |  | 89,049 |  |  | $ | 1.52 |  |  |  | 5.43 |
Granted |  |  | 16,778 |  |  | $ | 21.96 |  |  |  |  |
Exercised |  |  | (7,775 | ) |  | $ | 0.81 |  |  |  |  |
Forfeited |  |  | (1,593 | ) |  | $ | 15.09 |  |  |  |  |
Outstanding – December 31, 2022 |  |  | 96,459 |  |  | $ | 4.89 |  |  |  | 5.34 |
Exercisable – December 31, 2022 |  |  | 77,196 |  |  | $ | 1.48 |  |  |  | 4.36 |
No income tax benefit has been recognized relating to share-based compensation expense and no tax benefits have been realized from exercised share options. See also above regarding warrants granted to the underwriters upon the consummation of the IPO in consideration for their underwriting services.
| 3) | The following table summarize information as of December 31, 2023, regarding the number of ordinary shares issuable upon outstanding options and exercisable options:
Exercise price |  | Options outstanding as of December 31, 2023 |  |  | Weighted average remaining contractual life (years) |  |  | Options exercisable as of December 31, 2023 |  |  | Weighted average remaining contractual life (years) |
0.64 |  |  | 30,309 |  |  |  | 1.61 |  |  |  | 30,309 |  |  |  | 1.61 |
1.06 |  |  | 43,461 |  |  |  | 4.44 |  |  |  | 43,402 |  |  |  | 4.43 |
1.48 |  |  | 400 |  |  |  | 9.71 |  |  |  | 100 |  |  |  | 9.71 |
5.78 |  |  | 5,500 |  |  |  | 8.96 |  |  |  | 1,750 |  |  |  | 8.96 |
13.62 |  |  | 3,894 |  |  |  | 7.41 |  |  |  | 2,524 |  |  |  | 7.41 |
40.00 |  |  | 4,200 |  |  |  | 8.72 |  |  |  | 1,979 |  |  |  | 8.72 |
|  |  | 87,764 |  |  |  |  |  |  |  | 80,064 |  |  |  |  |
| 3) | The following table summarize information as of December 31, 2022, regarding the number of ordinary shares issuable upon outstanding options and exercisable options:
Exercise price |  | Options outstanding as of December 31, 2022 (*) |  |  | Weighted average remaining contractual life (years) |  |  | Options exercisable as of December 31, 2022 |  |  | Weighted average remaining contractual life (years) |
0.64 |  |  | 31,236 |  |  |  | 2.61 |  |  |  | 31,236 |  |  |  | 2.61 |
1.06 |  |  | 44,989 |  |  |  | 5.43 |  |  |  | 43,752 |  |  |  | 5.39 |
5.78 |  |  | 8,843 |  |  |  | 9.96 |  |  |  | - |  |  |  | - |
13.62 |  |  | 3,891 |  |  |  | 8.41 |  |  |  | 1,547 |  |  |  | 8.41 |
40.00 |  |  | 7,500 |  |  |  | 9.72 |  |  |  | 661 |  |  |  | 9.72 |
|  |  | 96,459 |  |  |  |  |  |  |  | 77,196 |  |  |  |  |
The aggregate intrinsic value represents the total intrinsic value (the difference between the fair value of the Company’s common shares on December 31, 2023 and the exercise price, multiplied by the number of options that would have been received by the option holders had all option holders exercised their options on such date) as of December 31, 2023, and December 31, 2022, was $17 and $291, respectively. The total intrinsic value of options exercised during the years ended December 31, 2023, and December 31, 2022, was $6 and $27, accordingly. The weighted average grant-date fair value of the share options granted during the year ended December 31, 2022 was $4.20, based on the Black-Scholes option-pricing model. Key assumptions used to estimate the fair value of the share options granted during the year ended December 31, 2022 included:
|  | 2022 |
Expected term of options (years) |  |  | 10 |
Expected common stock price volatility** |  |  | 54 | %
Expected dividend rate |  |  | 0 | %
Risk-free interest rate |  |  | 3.21%-3.25 | %
** | The expected volatility was based on the historical stock prices of publicly traded comparable companies.
| 4) | Share-based compensation expense for share options in the consolidated statements of comprehensive loss is summarized as follows:
|  | Year Ended December 31, |
|  | 2023 |  |  | 2022 |
Cost of revenues |  |  | 3 |  |  |  | 3 |
Research and development |  |  | 23 |  |  |  | 26 |
Sales and marketing |  |  | 11 |  |  |  | 11 |
General and administrative |  |  | 11 |  |  |  | 12 |
Total Share-based compensation expense |  |  | 48 |  |  |  | 52 |
| 5) | Restricted Stock Units (RSUs)
During 2023 and 2022, the Company issued RSUs to Directors, officers, consultants and employees. The RSUs are vested over a three-year period. The grant-date fair value of the RSUs granted was based on the Company’s common stock price at the time of grant. A summary of the Company’s RSUs activity under option plans is as follows:
|  | Year ended December 31, 2023 |  |  | Year ended December 31, 2022 |
|  | Number of RSUs |  |  | Weighted- Average Grant Date Fair Value |  |  | Number of RSUs (*) |  |  | Weighted- Average Grant Date Fair Value |
RSUs outstanding at the beginning of the year |  |  | 59,200 |  |  | $ | 16.20 |  |  |  | - |  |  |  | - |
Granted during the year |  |  | 43,100 |  |  | $ | 3.33 |  |  |  | 59,200 |  |  | $ | 16.20 |
Vested during the year |  |  | (29,520 | ) |  |  | 12.36 |  |  |  | - |  |  |  | - |
Forfeited during the year |  |  | (1,500 | ) |  |  | 16.20 |  |  |  | - |  |  |  | - |
Outstanding at the end of the year |  |  | 71,280 |  |  | $ | 10.35 |  |  |  | 59,200 |  |  | $ | 16.20 |
Share-based compensation expense for RSUs in the consolidated statement of comprehensive loss is summarized as follows:
|  | Year Ended December 31 |
|  | 2023 |  |  | 2022 |
|  | U.S. dollars in thousands |
Cost of revenues |  |  | 9 |  |  |  | 3 |
Research and development |  |  | 53 |  |  |  | 18 |
Sales and marketing |  |  | 47 |  |  |  | 12 |
General and administrative |  |  | 220 |  |  |  | 135 |
Total Share-based compensation expense |  |  | 329 |  |  |  | 168 |
As for the share-based compensation granted to the underwriter in connection with the offering of common stocks and warrants, see 14d above.
* | Adjusted to reflect reverse stock split, see note 2(ff).

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for equity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContent Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration